← BIOGEN INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $11.4b | $12.3b | $13.5b | $14.4b | $13.4b | $11.0b | $10.2b | $9.8b | $9.7b | $9.9b | |
| Cost of Revenue | $1.5b | $1.6b | $1.8b | $2.0b | $1.8b | $2.1b | $2.3b | $2.5b | $2.3b | $2.4b | |
| Gross Profit (derived) | $10.0b | $10.6b | $11.6b | $12.4b | $11.6b | $8.9b | $7.9b | $7.3b | $7.4b | $7.5b | |
| Operating Income (Loss) | $5.2b | $5.3b | $5.9b | $7.0b | $4.6b | $2.8b | — | — | — | — | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $385.6m | $814.7m | $381.2m | $274.0m | $255.1m | $252.0m | $246.3m | $240.6m | $386.5m | $507.1m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | ($50.0m) | $12.1m | $10.3m | $0 | $5.2m | ($2.0m) | $1.5m | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($9.8m) | $6.3m | ($9.9m) | ($7.0m) | ($10.7m) | ($22.4m) | $35.5m | $50.4m | $30.9m | $28.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $3.7b | $3.5b | $3.9b | $4.7b | $3.3b | $448.3m | $1.8b | $192.4m | $853.4m | $1.2b | |
| Income (Loss) from Equity Method Investments | $0 | $0 | $0 | ($79.4m) | $3.3m | $34.9m | $2.6m | $0 | $0 | — | |
| Realized Investment Gains (Losses) | — | — | — | — | $12.1m | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | — | — | — | — | $1.6b | |
| Net Income (Loss) Attributable to Parent | $3.7b | $2.5b | $4.4b | $5.9b | $4.0b | $1.6b | $3.0b | $1.2b | $1.6b | $1.3b | |
| Net Income (Loss) Attributable to Noncontrolling Interest | ($7.1m) | $131.0m | $43.3m | $0 | $59.9m | $171.5m | ($85.3m) | $400k | $0 | $0 | |
| Earnings Per Share, Basic | $16.96 | $11.94 | $21.63 | $31.47 | $24.86 | $10.44 | $20.96 | $8.02 | $11.21 | $8.83 | |
| Earnings Per Share, Diluted | $16.93 | $11.92 | $21.58 | $31.42 | $24.80 | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 | |
| Weighted Average Number of Shares Outstanding, Basic | 218.4m | 212.6m | 204.9m | 187.1m | 160.9m | 149.1m | 145.3m | 144.7m | 145.6m | 146.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 218.8m | 213.0m | 205.3m | 187.4m | 161.3m | 149.6m | 146.0m | 145.6m | 145.9m | 147.1m | |
| Selling, General and Administrative Expense | $1.9b | $1.9b | $2.1b | $2.4b | $2.5b | $2.7b | $2.4b | $2.5b | $2.4b | $2.4b | |
| Other Nonoperating Income (Expense) | ($217.4m) | ($13.1m) | ($10.5m) | ($47.0m) | $2.9m | ($5.6m) | $10.1m | $3.5m | $29.6m | ($24.7m) | |
| Costs and Expenses | $6.3b | $6.9b | $7.6b | $7.3b | $8.9b | $8.1b | $6.6b | $8.5b | $7.8b | $8.3b | |
| Current Income Tax Expense (Benefit) | $1.4b | $2.4b | $1.3b | $1.1b | $843.3m | $479.3m | $801.4m | $441.1m | $431.9m | ($98.0m) | |
| Interest Expense | $260.0m | $250.8m | $200.6m | $187.4m | $222.5m | $253.6m | $246.6m | $246.9m | $250.3m | $267.5m | |
| Restructuring Costs | $10.3m | — | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $1.2b | $2.5b | $1.4b | $1.2b | $992.3m | $52.5m | $632.8m | $135.3m | $273.8m | $263.6m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.